This is an HTML version of an attachment to the Freedom of Information request 'Documents regarding endocrine disrupters'.
Considerations on potency in the development of endocrine disruption regulatory criteria 
  
Potency is a fact of life 
  
The concept of potency can be evaluated through its intentional or unintentional consequences: 
potency explains why some drugs (pharmaceuticals) work better and/or at lower rate than others to 
address the same issue. It is the reason why sweeteners (of natural or synthetic origin) work at 
concentrations 100X (or more) lower than common sugar (saccharose). Potency explains why heroin 
is intrinsically more dangerous (and more severely regulated) than marijuana. 
Low potency is also the reason why we can safely consume daily a large number of food/drink items 
containing natural endocrine disruptors (natural phytoestrogens can be found in flaxseed, sesame 
seeds, pistachio nuts, sunflower seeds, chestnuts, almonds, walnuts, cashews, hazelnuts, soybeans, 
lentils, navy beans, kidney beans, pinto beans, fava beans, chickpeas, winter squash, green beans, 
collard greens, broccoli, cabbage, alfalfa sprouts, asparagus, carrots, green peppers, potatoes, 
zucchini, dried prunes, peaches, raspberries, strawberries, and grains [wheat, rye, oats and barley]). 
  
My proposed definition 
  
Potency is what distinguishes two substances that produce a similar (intentional or unintentional) 
effect in an intact organism (e.g. a human being); the substance that requires the lower dose to 
produce the effect is the more potent. 
  
Why is potency critical ? 
  
It is scientifically inappropriate to place in the same regulatory category the following substances: 
•        A substance that produces an adverse effect at a dose equivalent to 1 mg/kg 
bodyweight/day 
•        A substance that produces a  similar effect at 100 mg/kg bodyweight/day 
Placing them in the same regulatory category (e.g. a prohibition category) ignores the fact that the 
latter is less potent, intrinsically less hazardous and far less likely to cause problems than the former; 
it is also less likely to require significant mitigation measures to ensure safe uses.  
  
If potency is not taken into account, a large number of substances with tox/ecotox profiles of low 
concern will be amalgamated with ED substances of more serious regulatory concern. Whether the 
resulting consequences will be increased cost (more data required), lost uses (through REACH 
authorisations and restrictions) or complete prohibition, there will be loses of useful tools/solutions, 
with no contribution to a safer life or a safer environment. Removing from the market (uses of) 
substances of low concern will create problems where none exist. When decisions are not based on 
risk assessments but on hazard considerations,taking potency into account is virtually the only way 
to limit such loses: although it is a poor substitute for exposure evaluation in risk-based decisions 
(industry’s only supported approach), it minimizes the probability of making inaccurate regulatory 
decisions by distinguishing those substances that are of high concern from those that do not present 
risks under their normal conditions of use.   
  
GHS/CLP 
  
GHS and CLP are referred to as a justification for creating ED categories. Yet, the fact that potency is 
a fundamental principle of classification is ignored when considering whether potency should be a 
consideration for ED assignment. Potency clearly distinguishes categories for acute toxicity, aquatic 
toxicity, STOT effects, some physico-chemical properties, etc. The fact that ED often leads to CMR 
effects and these are not categorized by quantitative potency classes is often used as a reason to 

avoid potency considerations for ED assignment. In fact this is inaccurate, potency is taken into 
account when categorizing CMR effects, in a qualitative rather than quantitative manner: 
  
Excerpts from UNECE GHS: 
Chapter 3.6: Carcinogenicity 
Point 3.6.2: Classification criteria for substances 
Paragraph 3.6.2.7: ‘The relative hazard potential of a chemical is a function of its potency
There is great variability in potency among chemicals, and it may be important to account 
for these potency differences. The work that remains to be done is to examine methods for 
potency estimation. Carcinogenicity potency as used here
 [for classification purposes] does 
not preclude risk assessment
.’ 
 
Note: the idea that potency may be an intrinsic part of the carcinogenicity potential is clearly 
acknowledged in GHS. 
  
Excerpts from CLP (carcinogenicity): 
3.6.2.2.6. ‘Some important factors which may be taken into consideration [in 
carcinogenicity classification], when assessing the overall level of concern are: 
[…] 
(b) multi-site responses; 
(c) progression of lesions to malignancy; 
(d) reduced tumour latency; 
(e) whether responses are in single or both sexes; 
(f) whether responses are in a single species or several species; 
[…] 
(j) the possibility of a confounding effect of excessive toxicity at test doses;’ 
 
Note: all factors listed above are direct references to qualitative potency.   
The same CLP section also recognizes mutagenicity as a particularly important indicator for 
carcinogenicity potency: 
 
Mutagenicity: it is recognised that genetic events are central in the overall process of 
cancer development. Therefore evidence of mutagenic activity in vivo may indicate that a 
substance has a potential for carcinogenic effects.
’ 
  
Excerpts from CLP, Reprotox: 
3.7.2.4.1: ‘[…]In the interpretation of the developmental outcome to decide classification for 
developmental effects it is important to consider the possible influence of maternal toxicity. 
[…]’ 
 
Note: this is another qualitative reference to potency : substances that can harm the fetus in the 
absence of maternal toxicity are intrinsically more potent developmental toxins than others (with 
the former, protecting the mother won’t necessarily protect the fetus). The following excerpt 
confirms the above statement, by considering two different reprotox categories depending on the 
presence  or absence of maternal toxicity: 
 
3.7.2.4.3. ‘Classification shall not automatically be discounted for substances that produce 
developmental toxicity only in association with maternal toxicity, even if a specific 
maternally-mediated mechanism has been demonstrated. In such a case, classification in 
Category 2 may be considered more appropriate than Category 1.[…]’.